| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abiraterone acetate |
08.03.04.02 |
Formulary
|
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Abiraterone acetate |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Acetylcysteine (NAC) |
03.11 |
Non Formulary
|
NICE CG163: idiopathic pulmonary fibrosis diagnosis and management |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146: Psoriasis - adalimumab |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40) |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA 375 :Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383 - Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib |
| Afatinib |
08.01.05 |
Non Formulary
|
NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) |
| Afatinib |
08.01.05 |
Non Formulary
|
NICE TA 444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 307 - Aflibercept in combination with Irinotecan and Fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA294: aflibercept solution for injection for treating wet age-related macular degeneration |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA346 Aflibercept for treating diabetic macular oedema |
| Aflibercept |
08.01 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Alectinib |
08.01.05 |
Non Formulary
|
NICE TA438: Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.04 |
Formulary
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Amantadine Hydrochloride |
05.03.04 |
Formulary
|
NICE TA158 Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Antithymocyte immunoglobulin (rabbit) |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Antithymocyte immunoglobulin (rabbit) |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA 275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA 245:Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419 Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole (oral) |
04.02.01 |
Formulary
|
NICE TA292: aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
| Aripiprazole (oral) |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (only in adults with high levels of PD-L1) |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atomoxetine |
04.04 |
Formulary
|
NICE NG87: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. |
| Avelumab |
08.01.05 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
08.01.05 |
Formulary
|
Managed Access Agreement: Avelumab for treating metastatic Merkel cell carcinoma |
| Axicabtagene ciloleucel |
08.01.05 |
Restricted Use
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.01.03 |
Non Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults (replaces TA85) |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) |
| Belatacept |
08.02.02 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Belatacept |
08.02.02 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (CLL) |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Bevacizumab |
08.01.05 |
Non Formulary
|
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) |
| Bevacizumab |
08.01.05 |
Non Formulary
|
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118) |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA436: Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA212: Colorectal cancer (metastatic) - bevacizumab |
| Binimetinib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Bortezomib |
08.01.05 |
Non Formulary
|
NICE TA Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
In accordance with NICE TA 260 |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Bupropion |
04.10.02 |
Formulary
|
NICE PH45: tobacco: harm-reduction approaches to smoking. |
| Bupropion |
04.10.02 |
Formulary
|
NICE NG92 Stop smoking interventions and services |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 315 -Canagliflozin in combination therapy for treating type 2 diabetes |
| Canakinumab |
08.02.04 |
Formulary
|
NICE TA302: terminated TA on canakinumab for treating juvenile arthritis |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Carboplatin |
08.01.05 |
Formulary
|
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Carboplatin |
08.01.05 |
Formulary
|
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285) |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma |
| Cenegermin |
11.99.99.99 |
Non Formulary
|
NICE TA532: Cenegermin for treating neurotrophic keratitis |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA 415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA242:Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA172:Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck |
| Ciclosporin |
10.01.03 |
Formulary
|
NICE CG79 : Rheumatoid Arthritis |
| Ciclosporin 0.1% eye drops |
11.08.01 |
Formulary
|
NICE TA 369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cisplatin |
08.01.05 |
Formulary
|
Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer |
| Cladribine |
08.02.04 |
Formulary
|
NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Clomifene Citrate |
06.05.01 |
Formulary
|
NICE Clinical Guideline 156 Fertility problems: assessment and treatment |
| Clopidogrel |
02.09 |
Formulary
|
NICE CG94: unstable angina and NSTEMI |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Clozapine tablets |
04.02.01 |
Formulary
|
NICE CG178: psychosis and schizophrenia in adults, treatment and management. |
| Cobimetinib hemifumarate |
08.01.05 |
Non Formulary
|
NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colistimethate inhaler |
05.01.07 |
Formulary
|
NICE TA276: colistimethate sodium and tobramycin dry powder for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Collagenase |
10.03.01 |
Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for prevention of stroke and systemic embolism in atrial fibrillation |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA 157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA 249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA 327:Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabrafenib |
08.01.05 |
Non Formulary
|
NICE TA564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA:321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclatasvir |
05.03.03.02 |
Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Dalteparin |
02.08.01 |
Formulary
|
NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing. |
| Dalteparin |
02.08.01 |
Formulary
|
NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing. |
| Dalteparin |
02.08.01 |
Formulary
|
NICE CG 92 Venous thromboembolism: reducing the risk |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA454: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Darbepoetin |
09.01.03 |
Formulary
|
NG8 - Anaemia management in chronic kidney disease (Previously -NICE CG114) |
| Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab 120mg |
06.06.02 |
Formulary
|
NICE TA265: denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. |
| Denosumab 120mg |
06.06.02 |
Non Formulary
|
NICE TA549: Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) |
| Denosumab 60mg |
06.06.02 |
Formulary
|
NICE TA204: denosumab for the prevention of osteoporotic fractures in postmenopausal women. |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 349 Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamfetamine |
04.04 |
Formulary
|
NICE NG87: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Dimethyl fumarate |
13.05.02 |
Formulary
|
NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dinumtuximab |
08.01.05 |
Restricted Use
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Dipyridamole MR capsules |
02.09 |
Formulary
|
NICE TA210:Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA 355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA 354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA 354 Edoxaban for DVT and PE |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA 355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Elbasvir with Grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Elotuzumab |
08.01.05 |
Non Formulary
|
Elotuzumab for previously treated multiple myeloma |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471 eluxadoline for treating irritable bowel syndrome with diarrhoea for adults whose condition has not responded to other currently available treatments, or when these treatments are contraindicated or not tolerated |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 336 - Empagliflozin in combination therapy for treating type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Enoxaparin |
02.08.01 |
Formulary
|
NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Enzalutamide |
08.03.04.02 |
Formulary
|
Enzalutamide for metastatic hormonerelapsed prostate cancer previously treated with a docetaxel]containing regimen (TA316) |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA 377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (replaces TA250) |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (not recommended) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (not recommended) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE374: Erlotinib and Gefitinib for the treatment of non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA162) |
| Erlotinib |
08.01.05 |
Non Formulary
|
NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: etanercept and efalizumab for the treatment of adults with psoriasis. |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383:TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exemestane |
08.03.04.01 |
Formulary
|
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295) |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE TA112:Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults |
| Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NG28: exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (Previously NICE TA248) |
| Exenatide standard release injection |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes: management |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA 385: Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia |
| Faecal Microbiota Transplant |
05.06 |
Restricted Use
|
NICE IPG485: Faecal microbiota transplant for recurrent Clostridium difficile infection |
| Febuxostat |
10.01.04 |
Non Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout |
| Fidaxomicin |
05.01.07 |
Restricted Use
|
NICE Evidence summary ESNM1: Clostridium difficile infection: fidaxomicin |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97: Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone acetonide intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) |
| Fluorouracil |
08.01.03 |
Formulary
|
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Fluticasone furoate & vilanterol |
03.02 |
Formulary
|
NICE Evidence Summary [ESNM34] |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended) |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended) |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Gefitinib and erlotinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA175) (not recommended) |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell-lung cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE NG85: Pancreatic cancer in adults: diagnosis and management |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (not recommended) |
| Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glecaprevir with Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Glucosamine |
10.01.05 |
Non Formulary
|
NICE ’Do not do recommendation’ |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TND-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (previously NICE TA233) |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA 497 Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Holoclar® |
11.99.99.99 |
Restricted Use
|
NICE TA 467: Holoclar for treating limbal stem cell deficiency after eye burns |
| Human Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
| Human Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: routine antenatal anti-D prophylaxis for women who are rhesus D negative |
| Hyaluronic acid |
10.03.01 |
Non Formulary
|
NICE CG177: Osteoarthritis - care and management in adults |
| Hydroxychloroquine |
13.05.03 |
Formulary
|
NICE CG79 : Rheumatoid Arthritis |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ibandronic Acid |
06.06.02 |
Formulary
|
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ibrutinib |
08.01.05 |
Non Formulary
|
NICE TA452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) |
| Ibrutinib |
08.01.05 |
Non Formulary
|
NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429:Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Iloprost injection |
02.05.01 |
Formulary
|
NICE review of evidence |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70: guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Previously NICETA196) |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Non Formulary
|
NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Indapamide |
02.02.01 |
Formulary
|
NICE CG127: Hypertension in adults: diagnosis and management |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: adalimumab, etanercept, infliximab, rituximab and abtacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: etanercept inflximab and adalimumab for treatment of psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA 383 (Previously NICE TA143): TNF-alpha inhibitors for ankylosing spondylitis and non radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA 187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA 163 - Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA 134 - Infliximab for the treatment of adults with psoriasis |
| Inotuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Insulin (continuous subcutaneous infusion or CSII) |
06.01.01 |
Non Formulary
|
NICE TA151 CSII for the treatment of diabetes mellitus |
| Insulin Glargine |
06.01.01.02 |
Formulary
|
NG17 (previously NICE TA 53): Type 1 diabetes in adults: diagnosis and management |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Adefovir and peginteferon alfa-2a for the treatment of chronic hepatitis B. |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. |
| Interferon Beta-1a & Interferon Beta 1-b |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for untreated advanced (unresectable or metastatic) melanoma |
| Ispaghula Husk |
01.06.01 |
Formulary
|
NICE CG 61 Irritable Bowel Syndrome (IBS) |
| Ispaghula Husk |
01.06.01 |
Formulary
|
NICE CG 99 Constipation in children and young people |
| Ispaghula Husk |
01.06.01 |
Non Formulary
|
NICE CG61 Irritable Bowel Syndrome |
| Ispaghula Husk |
01.06.01 |
Non Formulary
|
NICE CG 99 Constipation in children and young people |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: management of stable angina |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Leflunomide |
10.01.03 |
Formulary
|
NICE CG79 : Rheumatoid Arthritis |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
| Liposomal Cytarabine-Daunorubicin |
08.01.05 |
Formulary
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Liraglutide |
06.01.02.03 |
Formulary
|
NG28 (previously NICE TA203): type 2 diabetes in adults : management |
| Lisdexamfetamine |
04.04 |
Formulary
|
NICE NG 87: Attention deficit hyperactivity disorder: diagnosis and management |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lutetium (177Lu) oxodotreotide |
08.01.05 |
Formulary
|
TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Mannitol |
03.07 |
Formulary
|
NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methylnaltrexone |
01.06.06 |
Non Formulary
|
NICE TA 468: Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) |
| Methylphenidate |
04.04 |
Formulary
|
NICE NG87: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186 (previously CG8): Multiple Sclerosis; management in primary and secondary care. |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naloxegol |
01.06.07 |
Formulary
|
NICE TA 345 Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Naltrexone for the management of opioid dependence |
| Naltrexone-bupropion |
04.05.02 |
Non Formulary
|
NICE TA494 Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA 411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.01.05 |
Non Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA 343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Ocrelizumab |
08.02.04 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA 344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA 470: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA202: Ofatumumab in chronic lymphocytic leukaemia |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Olaratumab |
08.01.05 |
Restricted Use
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Omalizumab |
13.05.03 |
Formulary
|
NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: omalizumab for treating severe persistent allergic asthma (review of TA133 + TA201) |
| Ombitasvir with Paritaprevir and Ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Orlistat |
04.05.01 |
Formulary
|
NICE CG43: Obesity prevention |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158. oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212) |
| Oxaliplatin |
08.01.05 |
Formulary
|
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307) |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer |
| Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Padeliporfin |
08.01.05 |
Non Formulary
|
NICE TA546: Padeliporfin for untreated localised prostate cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (not recommended) |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) |
| Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) |
| Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA242:Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: pazopanib for the first line treatment of advanced renal cell carcinoma |
| Pegaptanib |
11.08.02 |
Non Formulary
|
NICE TA155: guidance on pegaptanib in AMD (August 2008) |
| Pegaspargase |
08.01.05 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE CG 165: Hepatitis B (chronic) updates and replaces TA96 |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: adefovir, dipoxivin and peginterferon alfa2a for chronic hepatitis B |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pegylated Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Lung cancer (non-small-cell) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Penicillamine |
10.01.03 |
Formulary
|
NICE CG79 : Rheumatoid Arthritis |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Peristeen® |
01.05 |
Formulary
|
NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pioglitazone |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| pirfenidone |
20 |
Non Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone |
| Pirfenidone |
03.11 |
Restricted Use
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (previously NICE TA182) |
| Pregabalin |
04.03.04 |
Formulary
|
NICE CG113: Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA 211 Prucalopride for the treatment of chronic constipation in women |
| Quetiapine |
04.02.01 |
Formulary
|
NICE CG178: psychosis and schizophrenia in adults treatment and management |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raltitrexed |
08.01.03 |
Formulary
|
NICE CG131: Colorectal cancer: diagnosis and management |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA 403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283: ranibizumab for treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA155:Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298: ranibizumab for treatment of choroidal neovascularisation associated with pathological myopia |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274: Macular oedema (diabetic) - ranibizumab |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Stable Angina:Management |
| Recombinant human erythropoietins |
09.01.03 |
Formulary
|
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (NICE TA323) |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Non Formulary
|
NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of partial onset seizures in epilepsy |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106:peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200:peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor neurone disease |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Risperidone |
04.02.01 |
Formulary
|
NICE CG178: psychosis and schizophrenia in adults treatment and management |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: rivaroxaban for the prevention of VTE after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 The use of rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 287:Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with AF |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA 461 Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05 |
Formulary
|
NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA 485 Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350 Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Sertraline |
04.03.03 |
Formulary
|
NICE advice:First Choice Antidepressant Use in Adults with Depression or Generalised Anxiety Disorder |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA 331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Sitagliptin |
06.01.02.03 |
Formulary
|
NICE NG28. Type 2 diabetes in adults: management |
| Sodium Aurothiomalate |
10.01.03 |
Formulary
|
NICE CG79 : Rheumatoid Arthritis |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA 330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir with ledipasvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir with velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA431: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir with Velpatasvir and Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin (growth hormone) |
06.05.01 |
Formulary
|
NICE TA64: Human growth hormone (somatropin) in adults with human growth hormone deficiency |
| Somatropin (growth hormone) |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) |
| Sorafenib |
08.01.05 |
Formulary
|
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178) |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179) |
| Sunitinib |
08.01.05 |
Formulary
|
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178) |
| Sunitinib |
08.01.05 |
Formulary
|
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169) |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma (2nd line - not recommended) |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus (topical) |
13.05.03 |
Formulary
|
NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telbivudine |
05.03.03.01 |
Non Formulary
|
NICE TA154: Telbivudine for the treatment of chronic hepatitis B |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Temozolomide in recurrent malignant glioma (brain cancer) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Carmustin implants and temozolomide for newly diagnosed glioma |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma (not recommended) |
| Tenofovir alafenamide |
05.03.03.01 |
Non Formulary
|
NICE TA435: Tenofovir alafenamide for treating chronic hepatitis B |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing-remitting MS |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Acute coronary syndromes - ticagrelor |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tinzaparin |
02.08.01 |
Formulary
|
NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing |
| Tisagenlecleucel |
08.01.05 |
Restricted Use
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies |
| Tisagenlecleucel |
08.01.05 |
Restricted Use
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tisseel Ready-to-Use® |
16.01 |
Formulary
|
NICE IPG 60 |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: colistimethate sodium and tobramycin dry powder for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
01.05.03 |
Formulary
|
NICE TA 547 Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: topotecan for the treatment of relapsed small-cell lung cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Non Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Total parenteral nutrition (TPN) |
09.03 |
Formulary
|
NICE CG32: Nutrition support in adults |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: trabectedin for the treatment of advanced soft tissue sarcoma |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Non Formulary
|
NICE TA654: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA107: Breast cancer (early) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaces TA371) |
| Trifluridine–tipiracil |
08.01.03 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA 340 Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456-Ustekinumab for moderately to severe active crohn’s disease |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Vandetanib |
08.01.05 |
Non Formulary
|
NICE TA550: Vandetanib for treating medullary thyroid cancer - not recommended |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline for smoking cessation |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA 342 Vedolizumab in Ulcerative Colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA 352 Vedolizumab in Crohn’s |
| Vedolizumab |
10.01.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severe ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Non Formulary
|
NICE NG82: Age-related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vismodegib |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma (not recommended) |
| Zanamivir dry powder for inhalation |
05.03.04 |
Formulary
|
NICE TA 168: amantadine, oseltamavir and zanamavir for the treatment of influenza |
| Zanamivir dry powder for inhalation |
05.03.04 |
Formulary
|
NICE TA 158: oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza |
| Zoledronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
